from the fast evolving subject of oncology investigation, accurate and productive mutation screening is crucial for acquiring specific therapies. The KRAS providers Platform plays a pivotal part On this landscape by featuring detailed solutions for KRAS mutation profiling and Investigation. KRAS mutations, present in around 95% of RAS-similar oncog